Fineline Cube

Follow:
14486 Articles
RAPT Therapeutics Secures Ex-China Rights to Jemincare Group's Anti-IgE Antibody JYB1904
CompanyDeals

RAPT Therapeutics Secures Ex-China Rights to Jemincare Group’s Anti-IgE Antibody JYB1904

Porton Pharma and Dragon Sail Join Forces to Enhance ADC Drug Development
CompanyDeals

Porton Pharma and Dragon Sail Join Forces to Enhance ADC Drug Development

GSK's Jemperli Combo Shows Improved PFS in Phase III Ovarian Cancer Trial
CompanyDrug

GSK’s Jemperli Combo Shows Improved PFS in Phase III Ovarian Cancer Trial

Pfizer's Braftovi Receives FDA Approval for Metastatic Colorectal Cancer Treatment
CompanyDrug

Pfizer’s Braftovi Receives FDA Approval for Metastatic Colorectal Cancer Treatment

Eli Lilly's Zepbound Receives FDA Approval for Moderate-to-Severe OSA and Obesity
CompanyDrug

Eli Lilly’s Zepbound Receives FDA Approval for Moderate-to-Severe OSA and Obesity

Novo Nordisk's Alhemo Receives FDA Approval for Hemophilia A and B Prophylaxis
CompanyDrug

Novo Nordisk’s Alhemo Receives FDA Approval for Hemophilia A and B Prophylaxis

Boehringer Ingelheim-SEC Joint Incubator Launches in Shenzhen's Luohu District
Company

Boehringer Ingelheim-SEC Joint Incubator Launches in Shenzhen’s Luohu District

CStone Pharmaceuticals Initiates First-in-Human Trial for PD-1/VEGF/CTLA-4 Trispecific Antibody CS2009
CompanyDrug

CStone Pharmaceuticals Initiates First-in-Human Trial for PD-1/VEGF/CTLA-4 Trispecific Antibody CS2009

Becton, Dickinson and Co. Launches RMB1.332 Billion Factory in Jiangsu for Pre-Filled Syringes
CompanyMedical Device

Becton, Dickinson and Co. Launches RMB1.332 Billion Factory in Jiangsu for Pre-Filled Syringes

C.Q. Pharmaceutical Holding to Come Under SASAC's Indirect Control via Genertec Acquisition
CompanyDeals

C.Q. Pharmaceutical Holding to Come Under SASAC’s Indirect Control via Genertec Acquisition

Yifan Pharmaceutical's Evive Biotech Receives ANVISA Approval for Ryzneuta
CompanyDrug

Yifan Pharmaceutical’s Evive Biotech Receives ANVISA Approval for Ryzneuta

Changchun BCHT Biotechnology Receives NMPA Approval for HSV-2 mRNA Vaccine LVRNA101
CompanyDrug

Changchun BCHT Biotechnology Receives NMPA Approval for HSV-2 mRNA Vaccine LVRNA101